428 related articles for article (PubMed ID: 30390745)
21. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.
Fedson DS; Nicolas-Spony L; Klemets P; van der Linden M; Marques A; Salleras L; Samson SI
Expert Rev Vaccines; 2011 Aug; 10(8):1143-67. PubMed ID: 21810065
[TBL] [Abstract][Full Text] [Related]
22. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
23. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
Principi N; Esposito S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28029140
[TBL] [Abstract][Full Text] [Related]
24. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
Isturiz R; Webber C
Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
[TBL] [Abstract][Full Text] [Related]
25. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
[TBL] [Abstract][Full Text] [Related]
26. Use of pneumococcal polysaccharide vaccines: no simple answers.
French N
J Infect; 2003 Feb; 46(2):78-86. PubMed ID: 12634068
[TBL] [Abstract][Full Text] [Related]
27. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.
Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA
Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735
[TBL] [Abstract][Full Text] [Related]
28. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
29. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
30. Pneumococcal vaccines.
Ho CF; Lin TY
Chang Gung Med J; 2005 Nov; 28(11):765-72. PubMed ID: 16422182
[TBL] [Abstract][Full Text] [Related]
31. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
De Wals P; Black S; Borrow R; Pearce D
Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
[TBL] [Abstract][Full Text] [Related]
32. [Important: Pneumococcal protection for older people].
Heppner HJ
MMW Fortschr Med; 2024 Mar; 166(5):22-25. PubMed ID: 38514542
[No Abstract] [Full Text] [Related]
33. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
Suarez V; Michel F; Toscano CM; Bierrenbach AL; Gonzales M; Alencar AP; Ruiz Matus C; Andrus JK; de Oliveira LH
Vaccine; 2016 Sep; 34(39):4738-4743. PubMed ID: 27521230
[TBL] [Abstract][Full Text] [Related]
34. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
van Werkhoven CH; Bonten MJ
Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
[TBL] [Abstract][Full Text] [Related]
35. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
Ludwig E; Mészner Z;
Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
[TBL] [Abstract][Full Text] [Related]
36. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
Bonten MJ; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Gault S; van Werkhoven CH; van Deursen AM; Sanders EA; Verheij TJ; Patton M; McDonough A; Moradoghli-Haftvani A; Smith H; Mellelieu T; Pride MW; Crowther G; Schmoele-Thoma B; Scott DA; Jansen KU; Lobatto R; Oosterman B; Visser N; Caspers E; Smorenburg A; Emini EA; Gruber WC; Grobbee DE
N Engl J Med; 2015 Mar; 372(12):1114-25. PubMed ID: 25785969
[TBL] [Abstract][Full Text] [Related]
37. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
Mitchell R; Trück J; Pollard AJ
Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
[TBL] [Abstract][Full Text] [Related]
38. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age.
Lucero MG; Dulalia VE; Parreno RN; Lim-Quianzon DM; Nohynek H; Makela H; Williams G
Cochrane Database Syst Rev; 2004 Oct; (4):CD004977. PubMed ID: 15495133
[TBL] [Abstract][Full Text] [Related]
39. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in pneumococcal vaccination of children.
Russell FM; Mulholland EK
Ann Trop Paediatr; 2004 Dec; 24(4):283-94. PubMed ID: 15720885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
